MetaCap

Evommune Insider Trades

NYSE: EVMNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

6.25-0.16 (-2.50%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
7 · $70.16M
Sales
9 · $2.28M
Shares bought / sold
4.39M / 100.85K
Net activity
Net buying $67.9 million

Evommune insider activity

Over the last 12 months, Evommune insiders reported 48 transactions on SEC Form 4: 7 open-market purchases and 9 sales. Insiders bought $70.2 million and sold $2.3 million worth of stock, for net insider buying of $67.9 million. The largest seller was Pena Luis C., with $550,653 in reported sales.

The most recent filing shows Carver Kyle (Chief Financial Officer) buying 1,000 shares at $13.26 on Jul 8, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put EVMN's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

EVMN insider transactions

Evommune insider transactions
DateInsiderTypeSharesValueFiling
Jul 8, 2026Carver KyleChief Financial OfficerBuy1,000$13.26KForm 4
Jul 7, 2026KIRSCH ARTHUR SDirectorBuy10,000$133.00KForm 4
Jun 22, 2026Pena Luis C.President & CEOSale7,438$168.92KForm 4
Jun 22, 2026Drew Janice SuzannChief of Dev. OperationsSale20,000$452.60KForm 4
Jun 22, 2026Drew Janice SuzannChief of Dev. OperationsOption exercise16,161$48.32KForm 4
Jun 22, 2026Drew Janice SuzannChief of Dev. OperationsOption exercise3,839$14.74KForm 4
Jun 22, 2026Patel Jeegar PravinkumarChief Scientific OfficerSale1,488$33.48KForm 4
Jun 22, 2026Patel Jeegar PravinkumarChief Scientific OfficerOption exercise1,488$5.71KForm 4
Jun 2, 2026Cohen David EDirectorSale600$12.83KForm 4
Jun 2, 2026Cohen David EDirectorSale5,456$110.27KForm 4
Jun 1, 2026Patel Jeegar PravinkumarChief Scientific OfficerSale16,687$379.46KForm 4
Jun 1, 2026Patel Jeegar PravinkumarChief Scientific OfficerOption exercise13,512$51.89KForm 4
Jun 1, 2026Pena Luis C.President & CEOSale16,787$381.74KForm 4
May 28, 2026Moss Gregory S.Chief Business & Legal OfficerSale14,223$324.71KForm 4
May 28, 2026Moss Gregory S.Chief Business & Legal OfficerOption exercise14,223$24.32KForm 4
May 28, 2026Carver KyleChief Financial OfficerSale18,175$415.12KForm 4
May 28, 2026Carver KyleChief Financial OfficerOption exercise15,000$44.85KForm 4
Feb 17, 2026RA CAPITAL MANAGEMENT, L.P. & RA Capital Healthcare Fund LP & RA Capital Nexus Fund III, L.P. & Kolchinsky Peter & Shah Rajeev M.DirectorAward35,868$1000.00KForm 4
Feb 17, 2026Verduyn-van Weegen Felice IsabelDirectorAward358,680$10.00MForm 4
Feb 17, 2026LSP 7 Cooperative UADirectorAward358,680$10.00MForm 4
Dec 19, 2025Hopfner Robert LorneDirectorBuy1,000$17.35KForm 4
Dec 9, 2025Moss Gregory S.Chief Business & Legal OfficerTax withholding13,624$243.05KForm 4
Dec 9, 2025Bauer EugeneChief Medical OfficerTax withholding1,478$26.37KForm 4
Dec 9, 2025Carver KyleChief Financial OfficerTax withholding13,290$237.09KForm 4
Dec 9, 2025Drew Janice SuzannEVP, OperationsTax withholding5,074$90.52KForm 4
Dec 9, 2025Patel Jeegar PravinkumarChief Scientific OfficerTax withholding7,513$134.03KForm 4
Dec 9, 2025Pena Luis C.President & CEOTax withholding28,138$501.98KForm 4
Nov 7, 2025LSP 7 Cooperative UA10% OwnerBuy1,562,500$25.00MForm 4
Nov 7, 2025LSP 7 Cooperative UA10% OwnerConversion3,367,133—Form 4
Nov 7, 2025Carver KyleChief Financial OfficerConversion3,175—Form 4
Nov 7, 2025Cohen David EDirectorConversion6,056—Form 4
Nov 7, 2025Moss Gregory S.Chief Business & Legal OfficerConversion3,175—Form 4
Nov 7, 2025Patel Jeegar PravinkumarChief Scientific OfficerConversion3,175—Form 4
Nov 7, 2025Drew Janice SuzannEVP, OperationsConversion1,587—Form 4
Nov 7, 2025Hopfner Robert LorneDirectorConversion294,502—Form 4
Nov 7, 2025Hopfner Robert LorneDirectorConversion1,632,441—Form 4
Nov 7, 2025Hopfner Robert LorneDirectorConversion1,441,032—Form 4
Nov 7, 2025Hopfner Robert LorneDirectorConversion3,026—Form 4
Nov 7, 2025RA CAPITAL MANAGEMENT, L.P.DirectorBuy92,904$1.49MForm 4
Nov 7, 2025RA CAPITAL MANAGEMENT, L.P.DirectorBuy1,157,096$18.51MForm 4
Nov 7, 2025RA CAPITAL MANAGEMENT, L.P.DirectorConversion691,441—Form 4
Nov 7, 2025RA CAPITAL MANAGEMENT, L.P.DirectorConversion1,517,329—Form 4
Nov 7, 2025Pivotal bioVenture Partners Fund I, L.P. & Pivotal bioVenture Partners Fund I G.P., L.P. & Pivotal bioVenture Partners Fund I U.G.P. LtdDirectorConversion294,502—Form 4
Nov 7, 2025Pivotal bioVenture Partners Fund I, L.P. & Pivotal bioVenture Partners Fund I G.P., L.P. & Pivotal bioVenture Partners Fund I U.G.P. LtdDirectorConversion1,632,441—Form 4
Nov 7, 2025Pivotal bioVenture Partners Fund I, L.P. & Pivotal bioVenture Partners Fund I G.P., L.P. & Pivotal bioVenture Partners Fund I U.G.P. LtdDirectorConversion1,441,032—Form 4
Nov 7, 2025Pena Luis C.President & CEOConversion24,225—Form 4
Nov 7, 2025Verduyn-van Weegen Felice IsabelDirectorBuy1,562,500$25.00MForm 4
Nov 7, 2025Verduyn-van Weegen Felice IsabelDirectorConversion3,367,133—Form 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related